Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. Oktober 2017 08:30 ET | Quelle: Coherus BioSciences, Inc.

Coherus BioSciences to Report Third Quarter 2017 Financial Results on November 6th

REDWOOD CITY, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its third quarter 2017 financial results will be released after market close on...
07. September 2017 11:57 ET | Quelle: Coherus BioSciences, Inc.

Coherus BioSciences Provides Update on ‘619 IPR Institution Decision

REDWOOD CITY, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and...
01. September 2017 09:00 ET | Quelle: Coherus BioSciences, Inc.

Coherus BioSciences Management to Present at Three Investor Healthcare Conferences in September

REDWOOD CITY, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will present at three upcoming investor healthcare...
28. August 2017 08:30 ET | Quelle: Coherus BioSciences, Inc.

Coherus BioSciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420 (Humira® Biosimilar Candidate) versus European Marketed Humira in Healthy Subjects

REDWOOD CITY, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reported topline results from the first of three ongoing pharmacokinetic bioequivalence...
21. August 2017 08:30 ET | Quelle: Coherus BioSciences, Inc.

Coherus Secures Private Placement from Temasek

REDWOOD CITY, Calif., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced plans to raise up to $150 million in a two tranche private placement, the first...
07. August 2017 16:00 ET | Quelle: Coherus BioSciences, Inc.

Coherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results

REDWOOD CITY, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reviewed corporate events and reported financial results for the quarter ended June 30, 2017. ...
07. August 2017 09:00 ET | Quelle: Coherus BioSciences, Inc.

Coherus BioSciences Files Petition for Inter Partes Review of ENBREL® Patent 8,163,522

REDWOOD CITY, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that it has filed a petition for Inter Partes Review (“IPR”) in the United States...
24. Juli 2017 09:00 ET | Quelle: Coherus BioSciences, Inc.

Coherus BioSciences to Report Second Quarter 2017 Financial Results on August 7th

REDWOOD CITY, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its second quarter 2017 financial results will be released after market close on...
12. Juni 2017 06:37 ET | Quelle: Coherus BioSciences, Inc.

Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)

REDWOOD CITY, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response...
01. Juni 2017 09:00 ET | Quelle: Coherus BioSciences, Inc.

Coherus BioSciences Management to Present at 36th NASDAQ OMX Investor Program

REDWOOD CITY, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at the 36th NASDAQ OMX Investor Program on...

Vorherige Seite